Business
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg
About this update from Relay Therapeutics, Inc.
[{"type":"text","content":"Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + fulvestrant data: interim clinical benefit rate of 86% (6 of 7 evaluable patients) & 1 of 5 patients with measurable disease achieved a partial response Clinical benefit, including partial responses, observed across PI3Kα mutations and dose levels Approximately $872 million in cash, cash equivalents and investments at end of Q2 2023, expected to fund operations into second half of 2025 CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported second quarter 2023 financial results and corporate highlights. “In the second quarter of 2023, we continued to advance our pipeline and progress our breast cancer portfolio,” said Sanjiv Patel, M.D., president and chief executive officer of Relay Therapeutics. “In July, we initiated the first RLY-2608 + fulvestrant dose expansion cohort. The additional RLY-2608 data supporting this decision, and the breadth of our breast cancer franchise, continue to drive our confidence that we are building a comprehensive solution for the more than 100,000 patients diagnosed with PI3Kα-mutated breast cancer in the U.S. each year.” RLY-2608 Update In July 2023, initiated dose expansion cohort with RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutant, HR+, HER2– locally advanced or metastatic breast cancer Selection of 600mg BID dose supported by updated data from 17 breast cancer patients treated with RLY-2608 600mg BID + fulvestrant (cut-off date of July 24, 2023) Interim clinical benefit rate (CBR) of 86 percent (6 of 7 CBR-evaluable patients) (CBR defined as the proportion of patients with stable disease, complete response, or partial response for at least 24 weeks)Fifteen of 17 patients remain on treatment as of the cut-off dateOne of five efficacy-evaluable patients with measurable disease achieved a confirmed partial response (PR) and remains on treatment as of the cut-off date (helical mutation)Interim safety data compelling for use in metastatic breast cancer combinations Overall, updated data strengthen the RLY-2608 profile...